

Expression of B Cell Activating Factor (BAFF) and BAFF-binding Receptors in Rheumatoid Arthritis



It is widely accepted that B cells play an essential role in the pathogenesis of rheumatoid arthritis (RA). B cell involvement is well documented in the presence of detectable autoantibodies in the majority of patients, in particular, rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA), which can be detected many years before development of clinical disease, indicating that autoreactive B cell clones are involved in disease induction¹. B cell depletion therapy with rituximab (anti-CD20) is effective in treating RA, proving an essential role for B cells in disease persistence². Although B cell depletion therapy can induce longterm responses in a small number of patients, almost all patients eventually relapse.

There is therefore much interest in finding out whether analysis of B cell-related factors can guide the development of treatment strategies and/or prediction of disease flare. The cytokine B cell activating factor (BAFF; also known as BlyS) plays an essential role in B cell survival and homeostasis. BAFF binds to 3 different receptors: BAFF-R, TACI, and BCMA.

Expression of the different BAFF-binding receptors varies in distinct subsets of B cells, and their expression is coordinated and intimately related to maturation and activation status³.

In the study by Moura, *et al* in this issue of *The Journal*⁴, gene expression of molecules related to B cell survival and differentiation were studied in peripheral blood mononuclear cells (PBMC) in a small group of patients with very early RA (VERA; i.e., < 6 weeks of symptoms) and compared with other patients with RA at different stages [early RA (ERA) > 6 weeks and < 1 year duration; and established RA > 1 year duration], with patients with other forms of early arthritis (EA), and with healthy controls (HC). Patients with established RA were all taking methotrexate, and none were taking biologics. Samples for other groups were collected prior to treatment. The authors looked at gene expression of molecules involved in B cell homeostasis and survival (BAFF, BAFF-R, TACI, BCMA), class-switching (AID), chemotaxis (CXCR5), B cell

commitment and plasma cell differentiation (PAX5 and BLIMP-1), immune system activation (β_2 -microglobulin), and apoptosis (Bcl-2). The goals of the study were to provide insight into RA pathogenesis and identify potential biomarkers of disease progression.

The study found differences in gene expression of BAFF, BAFF-binding receptors (BAFF-R and TACI), and other B cell-related genes between patients with early and with established RA and HC⁴. BAFF-R gene expression was increased in patients with ERA and in established RA when compared with HC, but not in VERA or ERA. In addition, patients with established RA also had higher levels of BAFF-R gene expression compared to patients with VERA, suggesting that BAFF-R gene expression increases with disease progression. TACI gene expression was higher in all RA patient groups compared to HC, whereas no differences were seen between EA and HC. BAFF gene expression was only higher than in HC in patients with VERA. CXCR5 expression was higher only in patients with established RA. PAX5 gene expression was elevated in all RA groups in comparison with HC but especially in established RA. β_2 -microglobulin expression was higher in the groups with very early or early disease compared to those with established RA and HC. No differences were seen in BCMA, AID, BLIMP-1, and Bcl-2 gene expression. The authors report that no significant differences were seen between seropositive and seronegative patients, and also no correlations were found with measures of disease activity, that is, Disease Activity Score 28 or erythrocyte sedimentation rate.

There is much interest in the role of BAFF and its receptors in the pathogenesis of autoimmune diseases in terms of autoreactive B cell survival and function. The authors hypothesize that TACI gene expression is disturbed in RA from the onset of clinical disease and that BAFF-R expression increases with disease progression. Results were interpreted on the basis that these variations represented differences in expression of these receptors with functional consequences. They hypothesize that these changes may

See BAFF and TACI Gene Expression in Early RA, page 1293

occur in response to increased availability of serum BAFF and could be a protective response against excessive BAFF stimulation of autoreactive B cells through BAFF-R.

However, to our knowledge, there is no evidence that this system is disturbed in RA, and changes described in the study by Moura, *et al*⁴ could equally reflect relative changes in B cell subpopulations associated with the disease. This does not diminish the interest of this finding as it can help us develop hypotheses on the role that B cells and, in particular, different B cell subpopulations may play in the pathogenesis of RA. The problem is that in the absence of detailed data on protein expression and on relative proportions of B cells and B cell subpopulations in the PBMC samples, interpretation of the data is limited. Unfortunately, studies including all the necessary data for a detailed analysis are difficult to do, in particular because of costs and ethical limitations on the amount of blood needed from patients.

Therefore an alternative explanation is that the changes reflect differences in total numbers of circulating B cells and relative proportions of B cell subpopulations that are responding appropriately to the conditions present in RA. Some differences could reflect wider activation of other inflammatory cells able to express BAFF and β_2 -microglobulin very early in the disease. In established RA the differences found may be associated with increased proportions of activated circulating naive B cells reflected in increased TACI, PAX5, and possibly CXCR5 gene expression. As discussed later, the constant generation of such cells throughout the course of the disease may underlie apparent overexpression of certain B cell-associated genes.

Studies have shown that BAFF-R signaling in humans seems to be mainly a survival signal, with surface expression fairly uniform and similar between mature naive and memory B cells (BAFF-R is expressed on virtually 100% of CD19+ cells in peripheral blood)^{3,5}. In healthy individuals, BAFF-R is almost always occupied by BAFF in B cells outside the germinal center, in which supply is limited to favor T cell-driven antigen-specific responses^{3,6}. Also, when activated B cells undergo differentiation into immunoglobulin-secreting cells, BAFF-R expression decreases significantly. It is unlikely that increased BAFF-R gene expression could be explained by a relatively higher absolute number of circulating B cells within PBMC because frequencies and total B cells also tend to be slightly, but not significantly, lower in RA compared with HC⁷. Our group has indeed observed a tendency toward lower expression of BAFF-R in established RA compared with HC⁸. Increased BAFF-R gene expression in patients with established RA could thus be interpreted as representing increased turnover of BAFF-R due to an increased proportion of activated B cells as disease progresses. This would also explain the higher gene expression of CXCR5 in

established RA, which could reflect recirculation from inflamed synovium⁹.

TACI gene expression was found to be increased in all RA groups. As shown by Darce, *et al*³, all CD27+ memory B cells express TACI. It is unlikely that the increased TACI gene expression found was associated with increased numbers of memory B cells, as the opposite was described in VERA patients by the same group¹⁰. Darce, *et al*³ have also shown that a small, variable proportion of circulating naive (CD27-) B cells express TACI, which have an activated phenotype as defined by coexpression of CD25 and CD80. Some or all of this population may be analogous to the activated B cells described by Rudnicka, *et al*¹¹, which were found to show evidence of prior Toll-like receptor-9 (TLR) activation. Normal human naive B cells express only low levels of most TLR¹², supporting the view that an inappropriate "early" activation of B cells exiting the bone marrow occurs in RA¹¹.

BAFF gene expression was increased in VERA patients when compared to HC and established RA. However, BAFF serum levels, despite being clearly statistically significantly higher in patients with early RA, were still very low and probably within the normal range for the assay; for example, only 1 patient with VERA had levels higher than controls or 1 ng/ml. It is possible that increased expression of BAFF gene was associated with membrane BAFF, but not soluble BAFF, either by B cells¹³ or by other types of mononuclear cells in the sample. The significance of BAFF in RA has also been based on the finding of BAFF and BAFF-R gene expression in RA synovial tissue¹⁴. However, because BAFF-R is expressed on all B cells, this is to be expected because RA biopsy samples can include significant numbers of B cells and a number of infiltrating and somatic cells that produce BAFF. It is therefore difficult to ascribe any "control" of specific responses by the BAFF-R/BAFF system in such an inflammatory environment.

PAX5 expression is known to be higher in the naive B cell subpopulation¹⁵. Here, it was higher than in HC in all RA groups, especially in established RA. Increased PAX5 gene expression could therefore also be linked to increased proportions of naive B cells in the samples, which may also underly what was reported with TACI gene expression.

Increased serum levels of β_2 -microglobulin are usually considered a sign of B cell activation and have been shown to correlate with disease activity¹⁶. The results presented here, however, are difficult to interpret in the context of gene expression in PBMC samples because T cells and monocytes will express HLA class I molecules and therefore β_2 -microglobulin.

The use of rituximab in RA has focused research into the role of B cells in clinical response and relapse. Relapse or flare usually never occurs before B cell repopulation of the peripheral blood starts^{17,18}. Repopulation recapitulates ontogeny with increased proportions of transitional and

naive B cells. Although serum levels of autoantibodies can remain elevated throughout clinical remission, expansion or differentiation of cells into memory B cells and subsequently into autoantibody-producing plasmablasts is also associated with relapse^{18,19}. Our hypothesis is that clinical relapse is driven by naive autoreactive B cells, contributing directly to pathogenic autoantibody production or by reengaging perifollicular T cell help and memory B cell expansion²⁰. Such an hypothesis would therefore suggest the continuation of an acquired loss of central tolerance in patients with RA. This process can only be transiently disrupted by rituximab, which serves to prevent egress of “new” autoreactive B cells, but autoreactivity is hard-wired into the system. In patients where disease does not resume on repopulation, we would suggest that a critical mass of autoreactive B cell expansion needs to be achieved. Therefore, in RA, acquired defects in central tolerance may be important, but with additional roles also for expansion of autoreactive processes in the periphery.

Disturbances of central tolerance in patients with RA have been elegantly demonstrated by Samuels and colleagues²¹. Immunoglobulin transcripts with increased polyreactive and novel ACPA binding (not present in healthy controls) were shown to be produced from early emigrant B cells (CD10+IgD+) from patients with RA. These autoreactive B cells were also found to survive and mature into naive B cells (CD10–IgD+) in the periphery. Further evidence for the possibility that the autoimmune response is constantly being generated in these patients comes from observations that IgM-class ACPA are being recruited into the peripheral ACPA repertoire, thereby reflecting continuous reactivation of preswitched autoreactive B cells²².

It is not known what initiates RA, and therefore the study of patients with very early disease may provide clues as to what drives the immune process into full clinical expression. The results reported by Moura, *et al*⁴ represent an important contribution to our knowledge regarding expression of B cell-related factors in patients with the earliest signs of RA compared with those with established disease. The results could be interpreted to show that B cell homeostasis is indeed disrupted, but equally perhaps to suggest the presence of a naive activated B cell phenotype, detectable from the earliest stages of the disease. This information, combined with the unique opportunity to investigate the B cell biology underlying relapse following B cell-targeting therapies, gives us a realistic opportunity to inform the development of more targeted therapies capable of inducing longterm remission.

MARIA J. LEANDRO, MD, PhD;
GERALDINE CAMBRIDGE, PhD,
Department of Rheumatology,
University College London,
London, UK

Address correspondence to Dr. M.J. Leandro, Centre for Rheumatology Research, Division of Medicine, University College London, Rayne Building, 5 University Street, London WC1E 6JF, UK;
E-mail: maria.leandro@ucl.ac.uk

REFERENCES

1. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum* 2003;48:2741-9.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004;350:2572-81.
3. Darce J, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. *J Immunol* 2007;179:7276-86.
4. Moura R, Polido-Pereira J, Rodrigues A, Rodrigues AM, Navalho M, Mourão AF, et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. *J Rheumatol* 2013;40:1293-302.
5. Darce J, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. *J Immunol* 2007;178:5612-22.
6. Scholz JL, Cancro MP. Resolve, revise, and relax: The 3 Rs of B cell repertoire adjustment. *Immunol Lett* 2012;143:2-8.
7. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. *Arthritis Rheum* 2011;63:3692-701.
8. De la Torre I, Moura RA, Leandro MJ, Edwards JCW, Cambridge G. B-cell-activating factor expression on naïve and memory B cells: Relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. *Ann Rheum Dis* 2010;69:2181-8.
9. Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell’accio F, et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. *Arthritis Rheum* 2008;58:3377-87.
10. Moura RA, Weinmann P, Pereira PA, Caetano-Lopes J, Canhão H, Sousa E, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. *Rheumatology* 2010;49:1082-92.
11. Rudnicka W, Burakowski T, Warnawin E, Jastrzebska M, Bik M, Kontny E, et al. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients. *Eur J Immunol* 2009;39:1211-20.
12. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. *Blood* 2003;101:4500-4.
13. Abu-Rish EY, Amrani Y, Browning MJ. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. *Rheumatology* 2013; [Epub Feb 21].
14. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. *Scand J Rheumatol* 2007;36:365-72.
15. Kjeldsen MK, Perez-Andres M, Schmitz A, Johansen P, Boegsted M, Nyegaard M, et al. Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. *Am J Clin Pathol* 2011;136:960-9.

16. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. *Arthritis Res Ther* 2009;11:R114.
17. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. *Rheumatology* 2001;40:205-11.
18. Leandro MJ, Cambridge G, Ehrenstein M, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. *Arthritis Rheum* 2006;54:613-20.
19. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. *Arthritis Rheum* 2003;48:2164-54.
20. De la Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: Relationship with B-cell kinetics. *Rheumatology* 2012;51:833-40.
21. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. *J Exp Med* 2005;201:1659-67.
22. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. *Arthritis Rheum* 2006;54:3799-808.

J Rheumatol 2013;40:1247–50; doi:10.3899/jrheum.130677